Zusammenfassung
Für die Diagnose einer rheumatoiden Arthritis (RA) werden oft Klassifikationskriterien herangezogen. 2010 wurden die neuen ACR/EULAR-Klassifikationskriterien für die RA vorgestellt, die eine frühzeitigere Erfassung von Patienten erlauben, die ein hohes Risiko für eine chronisch-persistierende, erosiv verlaufende Arthritis aufweisen und damit der Definition einer RA entsprechen. Die Therapie mit krankheitsmodifizierenden Medikamenten sollte möglichst frühzeitig einsetzen. Methotrexat gilt als Standardtherapeutikum der ersten Wahl. Bei unzureichendem Ansprechen ist die Effektivität einer Biologikatherapie belegt. Für die Behandlung entscheidend ist die Definition des Therapieziels – in Frühfällen Remission, in späteren Stadien eine möglichst niedrige Krankheitsaktivität. Das Erreichen dieses Therapieziels sollte regelmäßig geprüft und die medikamentöse Therapie entsprechend angepasst werden.
Abstract
The diagnosis of rheumatoid arthritis (RA) is often based on classification criteria. In 2010 ACR and EULAR presented new classification criteria for RA which allow patients with a high risk for persistent, chronic and erosive arthritis and therefore fulfill the current definition of RA, to be defined. Therapy of RA should be initiated as early as possible. Methotrexate remains the first-line therapy of RA. In patients showing insufficient response of RA, biological agents have been demonstrated to be an effective second-line therapy. It is essential to define and follow an individual treatment target to obtain remission or low disease activity. This target should be reassessed regularly and treatment should be correspondingly adapted to achieve the target.
Literatur
Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
Allart CF, Huizinga TW (2011) Treatment strategies in recent onst rheumatoid arthritis. Curr Opin Rheumatol 23:241–244
Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413
Jones G, Sebba A, Gu J, Lowenstein MB (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96
Katchamart W, Trudeau J, Phumetum V et al (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112
Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681
Klarenbeek NB, Koevoets R, van der Heijde DM et al (2011) Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 70(10):1815–1821
Lillegraven S, Prince FHM, Shadick NA et al (2011) Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis [Epub ahead of print]
Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a cochrane systematic review. J Rheumatol 37(2):234–245
Moreland LW, O’Dell JR, Paulus HE et al (2009) TEAR: Treatment of Early aggressive RA; a randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum 60(Suppl):772 (Abstr 1895)
Ruiz Garcia V, Jobanputra P, Burls A et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev (2):CD007649
Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev (1):CD008341
Singh JA, Beg S, Lopez-Olivo MA (2011) Tocilizumab for rheumatoid arthritis: a cochrane systematic review. J Rheumatol 38:10–20
Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637
Smolen JS, Aletaha D (2011) Monitoring rheumatoid arthritis. Curr Opin Rheumatol 23:252–258
Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975
Smolen JS, Aletaha D, Keystone E (2005) Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum 52:2975–2983
Soubrier M, Puéchal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48:1429–1434
Todoerti M, Scirè CA, Boffini N et al (2010) Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci 1193:139–145
Van den Broek M, Huizinga TWJ, Dijkmans BAC et al (2011) Drug-free remission: is it already possible? Curr Opin Rheumatol 23:266–272
Van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH (2011) Classification of rheumatoid arthritis; comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/Eurpean League Against Rheumatism criteria. Arthritis Rheum 63:37–42
Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 69:1333–1337
Wollenhaupt J, Alten R, Backhaus M et al (2009) Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen. Akt Rheumatol 34(4):234–239
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Forschungsprojekte, Beratung und Vorträge für die Firmen Abbott, Amgen, AstraZeneca, BMS, Chugai, GlaxoSmithKline, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB (J.W.); Vorträge und Beratungstätigkeit für die Firmen Abbott, Bristol Myers Squibb, Medac, MSD, Pfizer, Roche, UCB (K.K.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wollenhaupt, J., Krüger, K. Frühe und fortgeschrittene rheumatoide Arthritis. Z. Rheumatol. 71, 53–63 (2012). https://doi.org/10.1007/s00393-011-0932-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-011-0932-1